Studies have shown that active fund managers routinely underperform the S&P500 index*​

Enliven Therapeutics, Inc. (NASDAQ: ELVN)

ELVN Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
-20.60%

ELVN Stock Analysis

ELVN PE Ratio:

ELVN PEG Ratio: Not Available

ELVN Forward EPS Growth (12 month): 0.00%

ELVN PS Ratio:

ELVN PSG Ratio: Not Available

ELVN Forward Revenue Growth (12 month): 0.00%

ELVN Articles

No data was found